Overview

European Sickle Cell Disease Cohort - Hydroxyurea

Status:
Completed
Trial end date:
2019-03-20
Target enrollment:
Participant gender:
Summary
In the context of the Risk Management Plan (RMP), as requested from Addmedica by the EMEA, to collect information about long-term safety of Siklos® (hydroxycarbamide) when used in patients with Sickle Cell Disease.
Details
Lead Sponsor:
ADDMEDICA SASA
Treatments:
Hydroxyurea